A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

"* Cycle 1: Day 1: 1 mg; Day 8: 2 mg; Day 15: 30 mg~* Cycles 2-8: 30 mg every 3 weeks~* Cycles 9-17: 30 mg every 3 weeks (if applicable） A treatment cycle is 21 days. Patients achieving complete remission (CR) by cycle 8 will stop treatment, while those with partial response (PR) or stable disease (SD) may continue up to 17 cycles or until disease progression or intolerable toxicity occurs."

\- Cycles 2-8: 200 mg IV every 3 weeks